Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease.

Hattori T, Orimo S, Hallett M, Wu T, Inaba A, Azuma R, Mizusawa H.

Acta Neurol Scand. 2014 Dec;130(6):347-53. doi: 10.1111/ane.12273.

The clinical spectrum of anxiety in Parkinson's disease.

Dissanayaka NN, White E, O'Sullivan JD, Marsh R, Pachana NA, Byrne GJ.

Mov Disord. 2014 Jul;29(8):967-75. doi: 10.1002/mds.25937. Review.

The use of antidepressant medication in Parkinson's disease patients is not affected by the type of antiparkinson medication.

Krøigård T, Christensen J, Wermuth L, Ritz B, Lassen CF.

J Parkinsons Dis. 2014;4(3):327-30. doi: 10.3233/JPD-140386.

Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients.

Malec-Litwinowicz M, Rudzińska M, Szubiga M, Michalski M, Tomaszewski T, Szczudlik A.

Neurol Neurochir Pol. 2014;48(4):258-61. doi: 10.1016/j.pjnns.2014.07.005.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S.

Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6.

Relationship between acoustic measures and judgments of intelligibility in Parkinson's disease: a within-speaker approach.

Feenaughty L, Tjaden K, Sussman J.

Clin Linguist Phon. 2014 Nov;28(11):857-78. doi: 10.3109/02699206.2014.921839.

Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review.

Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G.

Biomed Res Int. 2014;2014:728038. doi: 10.1155/2014/728038. Review.

Suprathreshold odor intensity perception in early-stage Parkinson's disease.

Doty RL, Beals E, Osman A, Dubroff J, Chung I, Leon-Sarmiento FE, Hurtig H, Ying GS.

Mov Disord. 2014 Aug;29(9):1208-12. doi: 10.1002/mds.25946.

History of smoking and olfaction in Parkinson's disease.

Lucassen EB, Sterling NW, Lee EY, Chen H, Lewis MM, Kong L, Huang X.

Mov Disord. 2014 Jul;29(8):1069-74. doi: 10.1002/mds.25912.

The functional role of beta oscillations in Parkinson's disease.

Little S, Brown P.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S44-8. doi: 10.1016/S1353-8020(13)70013-0. Review.

Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.

Mestre TA, Shah P, Marras C, Tomlinson G, Lang AE.

Neurology. 2014 Apr 22;82(16):1402-9. doi: 10.1212/WNL.0000000000000340.

Predicting dopaminergic effects of L-DOPA in the treatment for Parkinson's disease.

Navailles S, Di Giovanni G, De Deurwaerdère P.

CNS Neurosci Ther. 2014 Jul;20(7):699-701. doi: 10.1111/cns.12252. Review. No abstract available.

Humoral response against glial derived antigens in Parkinson's disease.

Papuć E, Kurzepa J, Kurys-Denis E, Grabarska A, Krupski W, Rejdak K.

Neurosci Lett. 2014 Apr 30;566:77-81. doi: 10.1016/j.neulet.2014.02.043.

Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies.

Wang P, Li J, Qiu S, Wen H, Du J.

Neuropsychiatr Dis Treat. 2014 Dec 31;11:59-66. doi: 10.2147/NDT.S69918.

Perceptions of living with a device-based treatment: an account of patients treated with deep brain stimulation for Parkinson's disease.

Hariz GM, Hamberg K.

Neuromodulation. 2014 Apr;17(3):272-7; discussion 277-8. doi: 10.1111/ner.12073.